[Plasma changes caused by estrogens in the vascular risk of prostatic carcinoma over a 3-year period].
作者信息
Daponte D P, Stevens I, Robinson M R
出版信息
Actas Urol Esp. 1986 Nov-Dec;10(6):437-40.
PMID:3825644
Abstract
摘要
相似文献
1
[Plasma changes caused by estrogens in the vascular risk of prostatic carcinoma over a 3-year period].[雌激素引起的血浆变化对前列腺癌血管风险的三年影响]
Actas Urol Esp. 1986 Nov-Dec;10(6):437-40.
2
French multicenter study on the use of estramustine phosphate versus diethylstilbestrol.
Prog Clin Biol Res. 1987;243B:229-34.
3
Estramustine phosphate vs diethylstilbestrol in the treatment of stage D prostate cancer.
Prog Clin Biol Res. 1989;303:177-86.
4
Estramustine phosphate versus stilbestrol as primary treatment for metastatic cancer of the prostate.
Can J Surg. 1983 Sep;26(5):434-8.
5
The EORTC Phase III trials in prostatic cancer.
Prog Clin Biol Res. 1985;185A:243-9.
6
7
8
A randomized double blind crossover trial of diethylstilbestrol (DES) and estramustine phosphate (Emcyt) for stage D prostatic carcinoma.
Semin Oncol. 1983 Sep;10(3 Suppl 3):43-5.
9
Estramustine for prostate cancer.
Med Lett Drugs Ther. 1982 Aug 6;24(615):74.
10
Treatment of advanced oestrogen-resistant prostatic carcinoma with estramustine phosphate.磷酸雌莫司汀治疗晚期雌激素抵抗性前列腺癌
Clin Oncol. 1981 Jun;7(2):163-5.
Zotero 插件